ClinicalTrials.gg
RecruitingNCT04935866NeurO2Updated Aug 18, 2022

Optimal Brain Oxygenation in Neurologic Intensive Care Unit : The NeurO2 Study

An observational study in Traumatic Brain Injury, Subarachnoid Hemorrhage and Brain Injuries, sponsored by CHU de Quebec-Universite Laval. Recruiting at 2 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-08-18.

Sponsored by CHU de Quebec-Universite Laval · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jul 2024, 2 years 4 months ago, but the record still lists the study as recruiting.
  • Started May 2021; still recruiting 5 years 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
286
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 69 studies in Brain Injuries, Traumatic with a site in Canada — 20 open to participants now, 22 under way, 2 of them phase 3. Brain Injuries, Traumatic · Canada.

Planned enrollment
6th of 18
286 · median 135
Started
2021
with 4 others
Observational
18 of 69
8 open now
Primary completion
2024-07
later than 1 of 21 live
Registered
55th of 69
by date
Lead sponsor
4 of 69
CHU de Quebec-Universite Laval

Among the 69 studies in Brain Injuries, Traumatic with a site in Canada, this one is the 6th largest by planned enrollment of the 18 observational ones that give a count, is one of 5 that started in 2021, is one of 18 observational ones, reaches primary completion later than 1 of the 21 other live ones, and was the 55th registered.

Brain Injuries, Traumatic

1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.

Browse Brain Injuries, Traumatic studies →

Open to participants now

20 of the 69 studies in Brain Injuries, Traumatic with a site in Canada are open now. Recruiting first, the newest first:

14 more — sign in →

All 20 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 69 studies in Brain Injuries, Traumatic with a site in Canada, or all of them as a file.
02

Study summary

The NeurO2 study is a multicenter observational study looking at NIRS monitoring in neurocrocritically ill patients during the acute phase of care following an acute brain injury. The study is nested within the HEMOTION Trial and the SAHaRA Trial

Read the detailed description

The NeurO2 study is a multicenter prospective study nested within two large-scale pragmatic randomized open blinded endpoint (PROBE) trials in neurocritically ill patients, the HEMOTION and the SAHaRa trials. These two trials are designed to compare a restrictive and a liberal transfusion strategies in critically ill patients with traumatic brain injury or subarachnoid hemorrhage. The NeurO2 will report on prospectively gathered regional cerebral oxygenation data (rSO2) from enrolled patients randomized to either the liberal or restrictive RBC transfusion strategy of their parent trials. The primary outcome will be 6-month neurologic function based on the GOSe. The established infrastructure of the trials will be used, including part of the data collection instruments and the outcome assessment team.

The NeurO2 study will achieve three separate but interconnected primary objectives: i) Evaluate if the cerebral hypoxemic burden as measured by NIRS during NICU stay, is associated with functional neurologic outcome (Glasgow Outcome Scale extended - GOSe) at 6 months, ii) Determine if the cerebral hypoxemic burden is impacted by red blood cell transfusion, iii) Determine if the level of response in cerebral hypoxemic burden after RBC transfusion is associated with the 6-month functional neurologic outcome (GOSe)

The secondary objectives are to evaluate whether the cerebral hypoxemic burden measured by NIRS is associated with other clinically relevant outcomes including ICU, hospital and 6-month mortality and hospital, ICU length of stay and quality of life.

03

Conditions studied

  • Traumatic Brain Injury
  • Subarachnoid Hemorrhage
  • Brain Injuries
  • Near-Infrared Spectroscopy
  • Intensive Care Neurological Disorder
  • Anemia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult patients hospitalized with a traumatic brain injury or with aneurysmal subarachnoid hemorrhage already enrolled in the HEMOTION Trial or the SAHaRA Trial

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Enrolment in one of the parent trials (HEMOTION or SAHaRA trials)
  • HEMOTION trial (acute moderate of severe blunt traumatic brain injury (Glasgow Coma Score18 [GCS] ≤ 12))
  • SAHaRA trial (acute subarachnoid hemorrhage as confirmed by treating neurosurgeon or neuro-interventionist and supported by blood in subarachnoid space resulting from a ruptured aneurysm)
  • Adult patients (age ≥18 years old)
  • Patients suffering from anemia ( ≤100 g/L)

Exclusion criteria

Exclusion criteria:

  • or known objections to blood transfusions
  • Active bleeding with hemodynamic instability at the time of enrollment
  • Decision to withdraw or withhold life-sustaining therapies made
  • NIRS monitoring not reliable
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
286 participants (estimated)
Patient registry
No

Interventions

  • OtherNear-infrared spectroscopy (NIRS)

    Non invasive brain oxygenation monitoring with Near-Infrared Spectroscopy (NIRS) technology. Patients enrolled in the NeurO2 study will have bilateral NIRS sensors applied to the forehead according to manufacturer recommendations. Data will be monitored continuously throughout the study intervention in the parent trials (HEMOTION and SAHaRA trials) in the neurocritical care unit. Data will be extracted from the device at the end of the study period.

06

What researchers measure

Primary outcomes

  1. Glasgow Outcome Scale extended

    The GOSe is an ordinal scale on 8 points evaluating the neurological functional outcome in neurocritically ill patients where 1 represents death and 8 the best possible outcome.

    Time frame: 6 months

Secondary outcomes

  1. Mortality

    Incidence of mortality

    Time frame: 6 months

  2. Hospital length of stay

    Duration of hospital stay for the index hospitalisation

    Time frame: through study completion, an average of 6 months

  3. ICU length of stay

    Duration of intensive care unit (ICU) stay for the index hospitalisation

    Time frame: through study completion, an average of 6 months

  4. EQ-5D-5L

    EQ-5D-5L is a standardised measure of health-related quality of life developed by the EuroQol Group. The EQ-5D-5L includes a 5-dimension questionnaire and an overall health question using a visual analogue scale (VAS). The 5 dimensions of the EQ-5D-5L are mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension is evaluated based on 5 levels (from the worst (1) to the best (5)). The overall health evaluation is based on a 100 point VAS where 100 means the optimal health

    Time frame: 6 months

07

Study locations

2 of 2 sites recruiting
  • The Ottawa Hospital
    Ottawa, Ontario, Canada
    Recruiting
    • Shane W English, MD MSc · Contact
  • CHU de Québec - Université Laval (Hôpital de l'Enfant-Jésus)
    Québec City, Quebec G1J-1Z4, Canada
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — To be determined

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2021 (actual). Primary completion is estimated for Jul 2024, 38 months after the start.

Of 231 non-industry observational studies under Brain Injuries, Traumatic, half reached primary completion within 50 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 95. This study's planned 38 months is below that.

Counting every sponsor, half of 253 studies reached it within 49 months; a quarter within 23 and three quarters within 95.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 15, 2021
First posted
Jun 23, 2021
StartActual
May 7, 2021
Primary completionEst.
Jul 2024
CompletionEst.
Jul 2025
Last update
Aug 18, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 18, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04935866
Collaborators
Ottawa Hospital Research Institute, Canadian Critical Care Trials Group, Canadian Traumatic Brain Injury Research Consortium
Responsible party
Dr Alexis Turgeon (Professor, CHU de Quebec-Universite Laval) — Principal investigator
First posted
Jun 23, 2021
Start date
May 7, 2021
Primary completion
Jul 2024 (estimated)
Completion
Jul 2025 (estimated)
Last update
Aug 18, 2022

Study contacts

Lucy Clayton, MSc
Contact
lucy.clayton.hsj@ssss.gouv.qc.ca
418-525-4444 ext. 64056
Angie Tuttle, MSc
Contact
antuttle@ohri.ca
613-737-8899 ext. 75084
Alexis F Turgeon, MD MSc FRCPC
principal investigator · CHU de Québec-Universite Laval Research Center, Universite Laval
Shane W English, MD MSc FRCPC
principal investigator · Ottawa Hospital Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion